According to Research.com Professor Dimitrios Buhalis was ranked 5th for “Best Business and Management Scientists in the United Kingdom” https://research.com/scientists-rankings/business-and-management/gb and 46th in the world (out of over 7,819 scientists). https://research.com/u/dimitrios-buhalis
The 2nd edition of Research.com ranking of the best scientists in the arena of Business and Management is based on data consolidated from various data sources including OpenAlex and CrossRef. The bibliometric data for estimating the citation-based metrics were gathered on December 21st, 2022. Position in the ranking is based on a scientist’s D-index (Discipline H-index), which only includes papers and citation values for an examined discipline. Our best scientists ranking is a reliable list of leading scientists from the area of Business and Management, based on a meticulous examination of 166,880 scientists discovered from various bibliometric data sources. For the discipline of Business and Management, over 7,819 were examined.
.
Professor Dimitrios Buhalis recognised as Highly Cited Researcher by Clarivate for the third year
The International Centre of Tourism and Hospitality Research [ICTHR] supports global tourism recovery from COVID. Professor Dimitrios Buhalis will deliver a range of keynotes, panels and interventions around the world. Please join us at these events.










BU academics publish in Nepal national newspaper
New BU Physiology paper
Gender and street names
Help Shape the Future of Research at BU: Postgraduate Research Experience Survey 2026 Now Open
3C Event: Research Culture, Community & Cherry Blossom – Tuesday 14 April
REMINDER: 3MT® Competition – Deadline 9am Monday 20 April
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease